1. Home
  2. SCLX vs AHT Comparison

SCLX vs AHT Comparison

Compare SCLX & AHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCLX
  • AHT
  • Stock Information
  • Founded
  • SCLX 2011
  • AHT 2003
  • Country
  • SCLX United States
  • AHT United States
  • Employees
  • SCLX N/A
  • AHT N/A
  • Industry
  • SCLX Biotechnology: Pharmaceutical Preparations
  • AHT Real Estate Investment Trusts
  • Sector
  • SCLX Health Care
  • AHT Real Estate
  • Exchange
  • SCLX Nasdaq
  • AHT Nasdaq
  • Market Cap
  • SCLX 35.7M
  • AHT 35.3M
  • IPO Year
  • SCLX N/A
  • AHT 2003
  • Fundamental
  • Price
  • SCLX $13.63
  • AHT $6.42
  • Analyst Decision
  • SCLX Strong Buy
  • AHT
  • Analyst Count
  • SCLX 3
  • AHT 0
  • Target Price
  • SCLX $367.50
  • AHT N/A
  • AVG Volume (30 Days)
  • SCLX 225.6K
  • AHT 29.0K
  • Earning Date
  • SCLX 08-12-2025
  • AHT 07-30-2025
  • Dividend Yield
  • SCLX N/A
  • AHT N/A
  • EPS Growth
  • SCLX N/A
  • AHT N/A
  • EPS
  • SCLX N/A
  • AHT N/A
  • Revenue
  • SCLX $50,710,000.00
  • AHT $1,143,655,000.00
  • Revenue This Year
  • SCLX $68.30
  • AHT N/A
  • Revenue Next Year
  • SCLX $124.48
  • AHT N/A
  • P/E Ratio
  • SCLX N/A
  • AHT N/A
  • Revenue Growth
  • SCLX 7.79
  • AHT N/A
  • 52 Week Low
  • SCLX $3.60
  • AHT $5.20
  • 52 Week High
  • SCLX $57.75
  • AHT $11.99
  • Technical
  • Relative Strength Index (RSI)
  • SCLX 65.59
  • AHT 50.53
  • Support Level
  • SCLX $10.14
  • AHT $6.20
  • Resistance Level
  • SCLX $17.76
  • AHT $6.75
  • Average True Range (ATR)
  • SCLX 1.79
  • AHT 0.31
  • MACD
  • SCLX 0.52
  • AHT -0.06
  • Stochastic Oscillator
  • SCLX 57.45
  • AHT 30.47

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About AHT Ashford Hospitality Trust Inc

Ashford Hospitality Trust Inc. is a real estate investment trust that invests in full-service upscale and upper-upscale hotel properties in the U.S. The company owns and operates its assets through its operating partnership, Ashford Hospitality Limited Partnership. All of its hotels are located across the U.S. and operate under the Marriott, Hilton, Hyatt, Crowne Plaza, and Sheraton brands. Ashford's sole segment is Direct Hotel Investments, through which it owns hotels by acquisition or development. Ashford also provides real estate investment services, such as mezzanine financing, first mortgage financing, and sales-leaseback transactions. Its revenue streams include Room revenue, Food and beverage revenue, and Other revenue. Room revenue accounts for the majority of total revenue.

Share on Social Networks: